サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1761154

抗肥満薬の世界市場規模・予測（2021年～2031年）、世界・地域シェア、動向、成長機会分析レポート：タイプ、薬剤クラス、用途、投与経路、流通チャネル、地域別

Anti-obesity Drugs Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Application, Route of Administration, and Distribution Channel, and Geography

出版日
ページ情報
英文 316 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
抗肥満薬の世界市場規模・予測（2021年～2031年）、世界・地域シェア、動向、成長機会分析レポート：タイプ、薬剤クラス、用途、投与経路、流通チャネル、地域別
出版日: 2025年06月20日
発行: The Insight Partners
ページ情報: 英文 316 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

弊社の最新調査レポート「抗肥満薬の世界市場予測（～2031年）- 世界分析：タイプ、薬剤クラス、用途、投与経路、流通チャネル、地域別」によると、市場規模は2024年の158億5,000万米ドルから成長し、2031年には1,772億7,000万米ドルに達すると予測され、2025年～2031年に35.3％のCAGRを記録すると予測されています。肥満の有病率の高まり、体重管理ソリューションに対する認識と需要の高まりが、抗肥満薬の市場規模拡大に寄与しています。しかし、副作用や安全性への懸念が抗肥満薬市場の成長を妨げています。さらに、精密医療と個別化された抗肥満薬レジメンは、今後数年間で新たな抗肥満薬市場動向をもたらすと予想されます。

収益では、北米が2024年の市場を独占しました。予測期間中も世界市場を独占すると予測されます。米国は世界最大の抗肥満薬市場です。糖尿病に伴う慢性創傷には、足潰瘍、静脈潰瘍、褥瘡などがあります。The International Journal of Tissue Repair and Regenerationによると、活動性または治癒した静脈性潰瘍は米国人口の1％に発生しています。米国疾病予防管理センター（CDC）の出版物であるNational Diabetes Statistics Report 2020によると、米国では全年齢層で3,420万人が糖尿病を患っており、毎年100万人の糖尿病患者が足潰瘍を発症し、600～700万人の糖尿病患者が生涯に潰瘍を発症しています。このように、糖尿病と慢性創傷の罹患率の増加は創傷被覆材の需要増につながり、予測期間中の抗肥満薬市場の成長に寄与しています。米国の企業は、有機的・無機的戦略を採用することで、プレゼンスの拡大に注力しています。2021年10月、Medline Industriesはカンザス州に新たな物流センターを建設するために7,750万米ドルを投資すると発表しました。

抗肥満薬市場の分析

新興国での拡大が今後の市場機会をもたらす

2023年7月に発表されたLancetの研究によると、インドでは2050年までに約4億5,000万人の成人が過体重または肥満になると予想されています。2021年には、過体重または肥満に分類される世界の成人の半数以上が以下の国々に集中しており、その数はインドで1億8,000万人、中国で4億200万人、ブラジルで8,800万人、ロシアで7,100万人、メキシコで5,800万人、インドネシアで5,200万人、エジプトで4,100万人です。

世界肥満連盟によると、ベトナム、インドネシア、バングラデシュでは肥満の有病率が上昇しており、その割合はここ数十年で6～9％となっています。都市化、座りがちなライフスタイル、食生活の変化により新興国で肥満の有病率が高まっているため、抗肥満薬の需要が高まっています。人口の大部分は未診断または未治療のままであり、製薬会社が新しい治療法を導入し、リーチを拡大するための未開拓市場となっています。イーライリリーは、2026年までにインド、ブラジル、メキシコで、減量・糖尿病治療薬ティルゼパチド（糖尿病治療薬Mounjaro、抗肥満薬Zepboundとして販売）を発売する準備を進めています。

ブラジルはヘルスケアインフラと肥満症管理プログラムを強化し、新たな抗肥満薬の導入と償還を支援する環境を育成しています。2024年4月、ブラジルはサンパウロ州ホルトランディアに、オゼンピックに含まれる有効成分リラグルチドを含む糖尿病・肥満症治療薬の生産に特化した研究所を開設しました。EMSが運営するこの工場では、オゼンピックの主要成分であるセマグルチドも生産されます。このセマグルチドは2026年3月まで有効な特許を有しており、すでにANVISA（Agencia Nacional de Vigilancia Sanitaria）の審査を受けています。6,000万レアル（約1,093万米ドル）を投資したこの施設はブラジル初のもので、連邦政府の健康経済産業複合体構想を支援するものです。

世界経済フォーラムによると、抗肥満薬への最初のアクセスは、民間市場と自己負担に限られる可能性があります。しかし、将来的には保険が適用され、中所得国でもジェネリック医薬品が使用されるようになれば、これらの医薬品へのアクセスが改善される可能性があります。このように、肥満率の上昇、政府の支援策、製品のイノベーションは、新興国市場に将来の成長機会をもたらすと期待されています。

抗肥満薬市場のセグメンテーション分析

抗肥満薬市場の分析に寄与した主要セグメントは、タイプ、薬剤クラス、投与経路、用途、流通チャネルです。

タイプ別では、抗肥満薬市場は処方薬とOTC医薬品に二分されます。2024年には、処方薬セグメントが比較的大きなシェアを占めました。

薬剤クラス別では、抗肥満薬市場はGLP-1アゴニスト、リパーゼ阻害薬、MC4Rアゴニスト、その他に区分されます。2024年にはGLP-1アゴニストセグメントが市場の最大シェアを占めました。GLP-1アゴニストセグメントはさらにセマグルチド、リラグルチド、ティルゼパチドに細分化されます。

用途別では、抗肥満薬市場は食欲抑制、脂肪吸収・消化酵素阻害、代謝促進、併用に分類されます。2024年の市場では、食欲抑制セグメントが最大のシェアを占めていました。

投与経路では、抗肥満薬市場は経口と非経口に二分されます。2024年には経口セグメントが市場を独占しました。

流通チャネル別では、抗肥満薬市場は院内薬局、オンラインチャネル、小売薬局に分類されます。2024年には院内薬局セグメントが市場を独占しました。

抗肥満薬市場：競合情勢と主な発展

ノボ・ノルディスクAS、イーライリリー・アンド・カンパニー、GSK Plc、リズム・ファーマシューティカルズInc、キュラックス・ファーマシューティカルズLLC、ビバスLLC、アドバケアファーマUSA LL、テバ・ファーマシューティカル・インダストリーズLtd、サン・ファーマシューティカル・インダストリーズLtd、F.ホフマン・ラ・ロシュLtdなどが抗肥満薬市場で事業を展開する主要企業です。

抗肥満薬市場レポートを作成する際に参照した一次情報および二次情報は、世界保健機関、世界肥満アトラス、米国食品医薬品局、ランセットジャーナル、世界肥満連盟、世界経済フォーラム、疾病管理予防センター（CDC）、国際糖尿病連盟（IDF）、経済協力開発機構（OECD）です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • アナリストの市場展望

第3章 調査手法

  • 2次調査
  • 1次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の作成
    • データの三角測量
    • 国レベルのデータ
  • 仮定と限界

第4章 抗肥満薬の市場情勢

  • PEST分析

第5章 抗肥満薬市場：主要市場力学

  • 抗肥満薬市場：主な市場力学
  • 市場促進要因
    • 肥満の蔓延
    • 体重管理ソリューションに対する認識と需要の高まり
  • 市場抑制要因
    • 副作用と安全性への懸念
  • 市場機会
    • 新興経済圏での拡大
  • 今後の動向
    • 精密医療と個別化抗肥満薬レジメン
  • 促進要因と抑制要因の影響

第6章 抗肥満薬市場：世界市場分析

  • 抗肥満薬市場の収益、2021年～2031年
  • 抗肥満薬市場の予測分析

第7章 抗肥満薬市場の分析：タイプ別

  • 処方薬
  • OTC医薬品

第8章 抗肥満薬市場の分析：薬剤クラス別

    GLP-1アゴニスト、リパーゼ阻害薬、MC4Rアゴニスト
  • GLP-1アゴニスト
  • リパーゼ阻害薬
  • MC4Rアゴニスト
  • その他

第9章 抗肥満薬市場の分析：用途別

  • 食欲抑制
  • 脂肪吸収・消化酵素阻害
  • 代謝促進
  • 併用

第10章 抗肥満薬市場の分析：投与経路別

  • 経口
  • 非経口

第11章 抗肥満薬市場の分析：流通チャネル別

  • 院内薬局
  • オンラインチャネル
  • 小売薬局

第12章 抗肥満薬市場の分析：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東・アフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第13章 業界情勢

  • 新製品開発/承認
  • その他の事業戦略

第14章 企業プロファイル

  • Novo Nordisk AS
  • Eli Lilly and Co
  • GSK Plc
  • Rhythm Pharmaceuticals Inc
  • Currax Pharmaceuticals LLC.
  • VIVUS LLC
  • AdvaCare Pharma USA LLC
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • F. Hoffmann-La Roche Ltd

第15章 企業概要付録

図表

List Of Tables

  • Table 1. Anti-Obesity Drugs Market Segmentation
  • Table 2. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million)
  • Table 3. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million)
  • Table 4. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 5. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 6. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 7. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 8. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 9. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 10. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 11. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 12. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 13. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 14. Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 15. Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 16. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 17. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 18. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 19. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 20. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 21. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 22. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 23. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 24. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 25. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 26. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 27. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 28. North America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 29. North America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 30. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 31. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 32. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 33. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 34. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 35. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 36. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 37. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 38. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 39. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 40. United States: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 41. United States: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 42. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 43. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 44. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 45. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 46. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 47. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 48. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 49. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 50. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 51. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 52. Canada: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 53. Canada: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 54. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 55. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 56. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 57. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 58. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 59. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 60. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 61. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 62. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 63. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 64. Mexico: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 65. Mexico: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 66. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 67. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 68. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 69. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 70. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 71. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 72. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 73. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 74. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 75. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 76. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 77. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 78. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 79. Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 80. ADULT OBESITY IN 2030
  • Table 81. CHILD OBESITY IN 2030
  • Table 82. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 83. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 84. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 85. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 86. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 87. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 88. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 89. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 90. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 91. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 92. Germany: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 93. Germany: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 94. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 95. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 96. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 97. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 98. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 99. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 100. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 101. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 102. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 103. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 104. United Kingdom: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 105. United Kingdom: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 106. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 107. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 108. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 109. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 110. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 111. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 112. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 113. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 114. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 115. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 116. France: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 117. France: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 118. ADULT OBESITY IN 2030
  • Table 119. CHILD OBESITY IN 2030
  • Table 120. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 121. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 122. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 123. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 124. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 125. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 126. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 127. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 128. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 129. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 130. Spain: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 131. Spain: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 132. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 133. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 134. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 135. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 136. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 137. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 138. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 139. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 140. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 141. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 142. Italy: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 143. Italy: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 144. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 145. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 146. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 147. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 148. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 149. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 150. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 151. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 152. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 153. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 154. Rest of Europe: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 155. Rest of Europe: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 156. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 157. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 158. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 159. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 160. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 161. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 162. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 163. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 164. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 165. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 166. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 167. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 168. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 169. Asia Pacific: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 170. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 171. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 172. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 173. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 174. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 175. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 176. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 177. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 178. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 179. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 180. China: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 181. China: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 182. ADULT OBESITY IN 2030
  • Table 183. CHILD OBESITY IN 2030
  • Table 184. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 185. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 186. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 187. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 188. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 189. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 190. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 191. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 192. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 193. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 194. Japan: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 195. Japan: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 196. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 197. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 198. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 199. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 200. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 201. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 202. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 203. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 204. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 205. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 206. India: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 207. India: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 208. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 209. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 210. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 211. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 212. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 213. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 214. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 215. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 216. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 217. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 218. Australia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 219. Australia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 220. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 221. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 222. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 223. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 224. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 225. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 226. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 227. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 228. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 229. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 230. South Korea: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 231. South Korea: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 232. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 233. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 234. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 235. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 236. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 237. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 238. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 239. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 240. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 241. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 242. Rest of APAC: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 243. Rest of APAC: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 244. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 245. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 246. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 247. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 248. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 249. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 250. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 251. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 252. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 253. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 254. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 255. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 256. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Country
  • Table 257. Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Country
  • Table 258. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 259. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 260. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 261. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 262. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 263. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 264. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 265. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 266. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 267. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 268. Saudi Arabia: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 269. Saudi Arabia: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 270. ADULT OBESITY IN 2030
  • Table 271. CHILD OBESITY IN 2030
  • Table 272. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 273. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 274. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 275. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 276. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 277. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 278. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 279. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 280. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 281. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 282. South Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 283. South Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 284. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 285. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 286. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 287. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 288. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 289. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 290. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 291. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 292. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 293. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 294. United Arab Emirates: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 295. United Arab Emirates: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 296. ADULT OBESITY IN 2030
  • Table 297. CHILD OBESITY IN 2030
  • Table 298. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 299. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 300. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 301. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 302. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Glp-1 Agonist
  • Table 303. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Glp-1 Agonist
  • Table 304. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 305. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 306. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Route Of Administration
  • Table 307. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route Of Administration
  • Table 308. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Distribution Channel
  • Table 309. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Distribution Channel
  • Table 310. South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2024 (US$ Million) - by Type
  • Table 311. South and Central America: Anti-Obesity Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Type
  • Table 312. South and Central America: Anti-Obesity Drugs Market - Revenue, 20

List Of Figures

  • Figure 1. Anti-Obesity Drugs Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Anti-Obesity Drugs Market Share (%) - by Type (2024 and 2031)
  • Figure 6. Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Anti-Obesity Drugs Market Share (%) - by Drug Class (2024 and 2031)
  • Figure 9. GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Anti-Obesity Drugs Market Share (%) - by Application (2024 and 2031)
  • Figure 14. Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Anti-Obesity Drugs Market Share (%) - by Route Of Administration (2024 and 2031)
  • Figure 19. Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Anti-Obesity Drugs Market Share (%) - by Distribution Channel (2024 and 2031)
  • Figure 22. Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Anti-Obesity Drugs Market Breakdown by Region, 2024 and 2031 (%)
  • Figure 26. North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 27. North America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 28. North America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 29. North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 30. North America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 31. North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 32. North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 33. North America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 34. United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 36. Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 37. Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 38. Europe: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 39. Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 40. Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 41. Europe: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 42. Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 43. Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 44. Europe: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 45. Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 47. France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 48. Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 49. Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 50. Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 51. Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 52. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 53. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 54. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 55. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 56. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 57. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 58. Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 59. China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 60. Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 61. India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 62. Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 63. South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 64. Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 65. Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 66. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 67. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 68. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 69. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 70. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 71. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 72. Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 73. Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 74. South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 75. United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 76. Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 77. South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 78. South and Central America: Anti-Obesity Drugs Market Breakdown, by Type (2024 and 2031)
  • Figure 79. South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class (2024 and 2031)
  • Figure 80. South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist (2024 and 2031)
  • Figure 81. South and Central America: Anti-Obesity Drugs Market Breakdown, by Application (2024 and 2031)
  • Figure 82. South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration (2024 and 2031)
  • Figure 83. South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel (2024 and 2031)
  • Figure 84. South and Central America: Anti-Obesity Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 85. Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 86. Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 87. Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
目次
Product Code: TIPRE00006850

According to our new research study on "Anti-obesity Drugs Market Forecast to 2031 -Global Analysis - by Type, Drug Class, Route of Administration, Application, Distribution Channel, and Geography," the market is anticipated to grow from US$ 15.85 billion in 2024 and is projected to reach US$ 177.27 billion by 2031; it is expected to register a CAGR of 35.3% during 2025-2031. Mounting prevalence of obesity and increased awareness and demand for weight management solutions are contributing to the growing anti-obesity drugs market size. However, the side effects and safety concerns hamper the anti-obesity drugs market growth. Further, precision medicine and personalized anti-obesity drug regimens is expected to bring in new anti-obesity drugs market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for anti-obesity drugs in the world. Chronic wounds associated with diabetes include foot, venous, and pressure ulcers. According to The International Journal of Tissue Repair and Regeneration, active or healed venous ulcers occur in 1% of the US population. As per the National Diabetes Statistics Report 2020, a publication of the Centers for Disease Control and Prevention (CDC), 34.2 million people of all ages in the US have diabetes, and ~1 million diabetics develop a foot ulcer each year, while 6-7 million diabetes patients develop ulcers in their lifetime. Thus, the rising incidence of diabetes and chronic wounds leads to an increase in demand for wound dressing and contributes to the anti-obesity drugs market growth during the forecast period. Companies in the US are focused on expanding their presence by adopting organic and inorganic strategies. In October 2021, Medline Industries announced an investment of US$ 77.5 million to build a new distribution center in Kansas.

Anti-obesity Drugs Market Analysis

Expansion in Emerging Economies to Provide Market Opportunities in Future

According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.

According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6-9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.

Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolandia, Sao Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026 and is already under review by Agencia Nacional de Vigilancia Sanitaria (ANVISA). With an investment of R$60 million (~US$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.

According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. Thus, the rising obesity rates, supportive government initiatives, and product innovations are expected to create future growth opportunities for the market in emerging countries.

Anti-obesity Drugs Market Report Segmentation Analysis

Key segments that contributed to the derivation of the anti-obesity drugs market analysis are type, drug class, route of administration, application, and distribution channel.

Based on type, the anti-obesity drugs market is bifurcated into prescription and OTC. The prescription segment held relatively larger share of the market in 2024.

By drug class, the anti-obesity drugs market is segmented into GLP-1 agonists, lipase inhibitors, MC4R agonists, and others. The GLP-1 Agonist segment held the largest share of the market in 2024. GLP-1 agonists segment further subsegmented into Semaglutide, Liraglutide, Tirzepatide.

Based on application, the anti-obesity drugs market is categorized into appetite suppression, inhibition of fat absorption/digestive enzymes, metabolic enhancement, and combination. The appetite suppression segment held a largest share of the market in 2024.

In terms of route of administration, the anti-obesity drugs market is bifurcated into oral and parenteral. The oral segment dominated the market in 2024.

Per distribution channel, the anti-obesity drugs market is categorized into hospital pharmacies, online channel, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Anti-obesity Drugs Market: Competitive Landscape and Key Developments

Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are among the key companies operating in the anti-obesity drugs market.

The World Health Organization, World Obesity Atlas, The U.S. Food and Drug Administration, The Lancet Journal, World Obesity Federation, World Economic Forum, Centers for Disease Control and Prevention (CDC), the International Diabetes Federation (IDF), the Organization for Economic Co-operation and Development (OECD) are primary and secondary sources referred to while preparing the anti-obesity drugs market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Anti-Obesity Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Anti-Obesity Drugs Market - Key Market Dynamics

  • 5.1 Anti-Obesity Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Mounting Prevalence of Obesity
    • 5.2.2 Increased Awareness and Demand for Weight Management Solutions
  • 5.3 Market Restraints
    • 5.3.1 Side Effects and Safety Concerns
  • 5.4 Market Opportunities
    • 5.4.1 Expansion in Emerging Economies
  • 5.5 Future Trends
    • 5.5.1 Precision Medicine and Personalized Anti-Obesity Drug Regimens
  • 5.6 Impact of Drivers and Restraints:

6. Anti-Obesity Drugs Market - Global Market Analysis

  • 6.1 Anti-Obesity Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Anti-Obesity Drugs Market Forecast Analysis

7. Anti-Obesity Drugs Market Analysis - by Type

  • 7.1 Prescription Drugs
    • 7.1.1 Overview
    • 7.1.2 Prescription Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 OTC Drugs
    • 7.2.1 Overview
    • 7.2.2 OTC Drugs: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Anti-Obesity Drugs Market Analysis - by Drug Class

  • 8.1 GLP-1 Agonist
    • 8.1.1 Overview
    • 8.1.2 GLP-1 Agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Lipase Inhibitors
    • 8.2.1 Overview
    • 8.2.2 Lipase Inhibitors: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 MC4R agonist
    • 8.3.1 Overview
    • 8.3.2 MC4R agonist: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Anti-Obesity Drugs Market Analysis - by Application

  • 9.1 Appetite Suppression
    • 9.1.1 Overview
    • 9.1.2 Appetite Suppression: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Inhibition of Fat Absorption or Digestive Enzymes
    • 9.2.1 Overview
    • 9.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Metabolic Enhancement
    • 9.3.1 Overview
    • 9.3.2 Metabolic Enhancement: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Combination
    • 9.4.1 Overview
    • 9.4.2 Combination: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Anti-Obesity Drugs Market Analysis - by Route Of Administration

  • 10.1 Oral
    • 10.1.1 Overview
    • 10.1.2 Oral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Parenteral
    • 10.2.1 Overview
    • 10.2.2 Parenteral: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. Anti-Obesity Drugs Market Analysis - by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Hospital Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.2 Online Channel
    • 11.2.1 Overview
    • 11.2.2 Online Channel: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Anti-Obesity Drugs Market - Revenue and Forecast to 2031 (US$ Million)

12. Anti-Obesity Drugs Market - Geographical Analysis

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 North America Anti-Obesity Drugs Market Overview
    • 12.2.2 North America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.2.3 North America: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.2.3.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.2.4 North America: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.2.4.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.2.4.1.1 North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.2.5 North America: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.2.5.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.2.6 North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.2.6.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.2.7 North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.7.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.2.8 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.2.8.1 North America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.2.8.2 United States: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.2.2 United States: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.2.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.2.3 United States: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.2.4 United States: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.2.5 United States: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.8.3 Canada: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.3.1 Canada: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.3.2 Canada: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.3.2.1 Canada: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.3.3 Canada: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.3.4 Canada: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.3.5 Canada: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.2.8.4 Mexico: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.2.8.4.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.2.8.4.2 Mexico: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.2.8.4.2.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.2.8.4.3 Mexico: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.2.8.4.4 Mexico: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.2.8.4.5 Mexico: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.3 Europe
    • 12.3.1 Europe Anti-Obesity Drugs Market Overview
    • 12.3.2 Europe: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.3.3 Europe: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.3.3.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.3.4 Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.3.4.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.3.4.1.1 Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.3.5 Europe: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.3.5.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.3.6 Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.3.6.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.3.7 Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.7.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.3.8 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.3.8.1 Europe: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.3.8.2 Germany: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.2.2 Germany: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.2.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.2.3 Germany: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.2.4 Germany: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.2.5 Germany: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.3 United Kingdom: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.3.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.3.2 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.3.2.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.3.3 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.3.4 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.3.5 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.4 France: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.4.1 France: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.4.2 France: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.4.2.1 France: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.4.3 France: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.4.4 France: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.4.5 France: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.5 Spain: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.5.1 Spain: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.5.2 Spain: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.5.2.1 Spain: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.5.3 Spain: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.5.4 Spain: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.5.5 Spain: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.6 Italy: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.6.1 Italy: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.6.2 Italy: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.6.2.1 Italy: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.6.3 Italy: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.6.4 Italy: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.6.5 Italy: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.3.8.7 Rest of Europe: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.3.8.7.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.3.8.7.2 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.3.8.7.2.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.3.8.7.3 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.3.8.7.4 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.3.8.7.5 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.4 Asia Pacific
    • 12.4.1 Asia Pacific Anti-Obesity Drugs Market Overview
    • 12.4.2 Asia Pacific: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.4.3 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.4.3.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.4.4 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.4.4.1.1 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.4.5 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.4.5.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.4.6 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.4.6.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.4.7 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.7.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.4.8 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.4.8.1 Asia Pacific: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.4.8.2 China: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.2.1 China: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.2.2 China: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.2.2.1 China: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.2.3 China: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.2.4 China: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.2.5 China: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.3 Japan: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.3.1 Japan: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.3.2 Japan: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.3.2.1 Japan: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.3.3 Japan: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.3.4 Japan: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.3.5 Japan: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.4 India: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.4.1 India: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.4.2 India: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.4.2.1 India: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.4.3 India: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.4.4 India: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.4.5 India: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.5 Australia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.5.1 Australia: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.5.2 Australia: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.5.2.1 Australia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.5.3 Australia: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.5.4 Australia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.5.5 Australia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.6 South Korea: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.6.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.6.2 South Korea: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.6.2.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.6.3 South Korea: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.6.4 South Korea: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.6.5 South Korea: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.4.8.7 Rest of APAC: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.4.8.7.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.4.8.7.2 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.4.8.7.2.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.4.8.7.3 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.4.8.7.4 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.4.8.7.5 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.5 Middle East and Africa
    • 12.5.1 Middle East and Africa Anti-Obesity Drugs Market Overview
    • 12.5.2 Middle East and Africa: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.5.3 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.5.3.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.5.4 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.5.4.1.1 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.5.5 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.5.5.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.5.6 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.5.6.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.5.7 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.7.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.5.8 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.5.8.1 Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.5.8.2 Saudi Arabia: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.2.2 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.2.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.2.3 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.2.4 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.2.5 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.3 South Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.3.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.3.2 South Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.3.2.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.3.3 South Africa: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.3.4 South Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.3.5 South Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.4 United Arab Emirates: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.4.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.4.2 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.4.2.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.4.3 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.4.4 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.4.5 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.5.8.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.5.8.5.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.5.8.5.2 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.5.8.5.2.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.5.8.5.3 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.5.8.5.4 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.5.8.5.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
  • 12.6 South and Central America
    • 12.6.1 South and Central America Anti-Obesity Drugs Market Overview
    • 12.6.2 South and Central America: Anti-Obesity Drugs Market - Revenue, 2021-2031 (US$ Million)
    • 12.6.3 South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
      • 12.6.3.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Type
    • 12.6.4 South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
      • 12.6.4.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 12.6.4.1.1 South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
    • 12.6.5 South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
      • 12.6.5.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Application
    • 12.6.6 South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
      • 12.6.6.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Route Of Administration
    • 12.6.7 South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.7.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Distribution Channel
    • 12.6.8 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.6.8.1 South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast Analysis - by Country
      • 12.6.8.2 Brazil: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.2.2 Brazil: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.2.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.2.3 Brazil: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.2.4 Brazil: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.2.5 Brazil: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.8.3 Argentina: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.3.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.3.2 Argentina: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.3.2.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.3.3 Argentina: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.3.4 Argentina: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.3.5 Argentina: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
      • 12.6.8.4 Rest of South and Central America: Anti-Obesity Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 12.6.8.4.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Type
        • 12.6.8.4.2 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class
          • 12.6.8.4.2.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
        • 12.6.8.4.3 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Application
        • 12.6.8.4.4 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
        • 12.6.8.4.5 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 New Product Development/Approval
  • 13.3 Other Business Strategies

14. Company Profiles

  • 14.1 Novo Nordisk AS
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
  • 14.2 Eli Lilly and Co
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 GSK Plc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
  • 14.4 Rhythm Pharmaceuticals Inc
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Currax Pharmaceuticals LLC.
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 VIVUS LLC
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 AdvaCare Pharma USA LLC
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
  • 14.8 Teva Pharmaceutical Industries Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
  • 14.9 Sun Pharmaceutical Industries Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 F. Hoffmann-La Roche Ltd
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms